Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | F2R | P25116 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770442 | 0.82 | HSD11B1 (0.42) | CHRM1LMNAHSD11B1EPHX2ITGB3 | |
| SCHEMBL770918 | 0.82 | ITGB3 (0.45) | CHRM1LMNAHSD11B1EPHX2ITGB3 | |
| SCHEMBL772269 | 0.82 | ATM (0.44) | CHRM1LMNAHSD11B1EPHX2ITGB3 | |
| SCHEMBL770761 | 0.82 | ATM (0.44) | CHRM1LMNAHSD11B1EPHX2ITGB3 | |
| SCHEMBL771875 | 0.82 | ATM (0.44) | CHRM1LMNAHSD11B1EPHX2ITGB3 | |
| SCHEMBL770719 | 0.80 | EPHX2 (0.46) | CHRM1LMNAHSD11B1EPHX2ITGB3 | |
| SCHEMBL794632 | 0.78 | EPHX2 (0.47) | CHRM1LMNAHSD11B1EPHX2KDM4E | |
| SCHEMBL10138022 | 0.77 | ALDH1A1 (0.41) | CHRM1LMNAHSD11B1ITGB3ITGA2B | |
| SCHEMBL770904 | 0.76 | HSD11B1 (0.50) | HSD11B1ITGB3ITGA2BHTTMBTD1 | |
| SCHEMBL770235 | 0.76 | NPC1 (0.49) | CHRM1LMNAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | CHRM1 3021/4885LMNA 3116/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.